The company also offers platform-agnostic next-generation sequencing tests and a suite of sample prep and thermal cycling instruments.

The Boston-based digital pathology firm's updated US Food and Drug Administration clearance will help it to quickly validate its software with new hardware combinations.

The firm saw growth in its core laboratory segment but declines in molecular, point of care, and rapid diagnostics.

NEW YORK – Phase Scientific said Wednesday that has signed an exclusive US distribution agreement with Lumos Diagnostics for a 10-minute point-of-care blood test to distinguish bacterial and ...

NEW YORK – The US Food and Drug Administration in June granted 510(k) marketing clearances for infectious disease tests, digital pathology software, and hematology analyzers, among other in vitro ...

The agency said that the test is unnecessary for the screening of whole blood and blood components that are screened with nucleic acid tests and core antigen tests.

Agilent Technologies said that Robert McMahon will resign from as the company's senior vice president and chief financial officer, effective July 31 for family reasons. Rodney Gonsalves, Agilent's ...

The company's next-generation sequencing-based test is used to aid the detection of cancers in patients with indeterminate ...

NEW YORK – Bio-Techne on Tuesday announced a strategic partnership to distribute Spear Bio's immunoassays for detecting low-abundance biomarkers in neurology. The assays include Alzheimer's disease ...